Chagas Disease: Perspectives on the Past and Present and Challenges in Drug Discovery.

Abstract

Chagas disease still has no effective treatment option for all of its phases despite being discovered more than 100 years ago. The development of commercial drugs has been stagnating since the 1960s, a fact that sheds light on the question of how drug discovery research has progressed and taken advantage of technological advances. Could it be that technological advances have not yet been sufficient to resolve this issue or is there a lack of protocol, validation and standardization of the data generated by different research teams? This work presents an overview of commercial drugs and those that have been evaluated in studies and clinical trials so far. A brief review is made of recent target-based and phenotypic studies based on the search for molecules with anti-Trypanosoma cruzi action. It also discusses how proteochemometric (PCM) modeling and microcrystal electron diffraction (MicroED) can help in the case of the lack of a 3D protein structure; more specifically, Trypanosoma cruzi carbonic anhydrase.

• Authors: Felipe Raposo Passos Mansoldo, Fabrizio Carta, Andrea Angeli, Veronica da Silva Cardoso, Claudiu T Supuran, Alane Beatriz Vermelho
• Journal: Molecules (Basel, Switzerland) (Molecules) Vol. 25 Issue 22 (Nov 23 2020) ISSN: 1420-3049 [Electronic] Switzerland
• PMID: 33238613 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers
• Trypanocidal Agents

Topics

• Biomarkers
• Chagas Disease (drug therapy, parasitology)
• Drug Design
• Drug Discovery (methods, trends)
• Humans
• Models, Molecular
• Molecular Targeted Therapy
• Structure-Activity Relationship
• Trypanocidal Agents (chemistry, pharmacology, therapeutic use)
• Trypanosoma cruzi (drug effects)